Idelalisib

Especificaciones

870281-82-6Número CAS

807-438-9Número CE

5-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]quinazolin-4-oneNombre IUPAC

C22H18FN7OFórmula química

415.4 g/molPeso molecular

Idelalisib; 870281-82-6; CAL-101; Zydelig; GS-1101; CAL101; GS 1101; YG57I8T5M0; 5-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]quinazolin-4-one; 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one; CHEBI:82701; DTXSID701007266; 5-fluoro-3-phenyl-2-[(1S)-1-(3H-purin-6-ylamino)propyl]quinazolin-4(3H)-one; 5-fluoro-3-phenyl-2-[(1S)-1-[(9H-purin-6-yl)amino]propyl]-3,4-dihydroquinazolin-4-one; idelalisibum; 5-fluoro-3-phenyl-2-((1S)-1-(7H-purin-6-ylamino)propyl)quinazolin-4-one; 5-fluoro-3-phenyl-2-((1S)-1-((9H-purin-6-yl)amino)propyl)-3,4-dihydroquinazolin-4-one; 5-fluoro-3-phenyl-2-((1S)-1-(3H-purin-6-ylamino)propyl)quinazolin-4(3H)-one; RefChem:58018; L01XX47; DTXCID901434124; Phosphoinositide-3 Kinase Delta Inhibitor CAL-101; CAL 101; (S)-2-(1-((9H-Purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; Idelalisib (CAL-101); CAL-101 (Idelalisib, GS-1101); C22H18FN7O; 5-FLUORO-3-PHENYL-2-[(1S)-1-(9H-PURIN-6-YLAMINO)PROPYL]-4(3H)-QUINAZOLINONE; MFCD19443647; CHEMBL2216870; 4(3H)-Quinazolinone,5-fluoro-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)propyl]-; CAL-101 (GS-1101); Idelalisib; CAL-101; (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; GS-1101; Idelalisib; CAL-101; 4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-; 5-Fluoro-3-Phenyl-2-[(1s)-1-(7h-Purin-6-Ylamino)propyl]quinazolin-4(3h)-One; Idelalisib [INN]; Idelalisib [USAN:INN]; UNII-YG57I8T5M0; Idealisib; Zydelig (TN); IDELALISIB [MI]; IDELALISIB [JAN]; 1453810-72-4; IDELALISIB [USAN]; CAL-101 (Idelalisib); IDELALISIB [VANDF]; IDELALISIB [WHO-DD]; MLS006010985; Idelalisib (JAN/USAN/INN); SCHEMBL356400; GTPL6741; orb1219666; orb1223795; orb1307216; orb3141423; IDELALISIB [ORANGE BOOK]; SCHEMBL16782604; SCHEMBL29354482; SCHEMBL29411768; SCHEMBL29422886; HSDB 8408; CAL-101/CAL101; EX-A330; GS-11CAL-101; GLXC-90121; EX-A1242; BDBM50403068; EBC-24030; NSC759224; NSC762828; NSC800771; s2226; AKOS022186334; AKOS040744041; Idelalisib (CAL-101,GS-1101); CCG-264949; CS-0256; DB09054; FI29231; NSC-759224; NSC-762828; NSC-800771; SDCCGSBI-0654408.P001; NCGC00262603-01; NCGC00262603-02; NCGC00262603-04; NCGC00262603-08; AC-28394; AC-36641; HY-13026; IC489666; SMR004702787; DB-333007; NS00071041; SW219823-1; A-1138; D10560; EN300-7412931; Q5908266; BRD-K60866521-001-01-4; BRD-K60866521-001-07-1; (S)-2-(1-(1-(9H-Purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; (S)-5-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one; 5-Fluoro-3-phenyl-2-{(1S)-1-[(9H-purin-6-yl)amino]propyl}quinazolin-4(3H)-one; IDELALISIBCT-CAL101IDEALISIBCAL-101CAL 101GS-1101GS 1101ZYDELIGA-1138CAL101; 40LSinónimos